Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer

Fowler, Amy M.; Clark, Amy S.; Katzenellenbogen, John A.; Linden, Hannah M.; Dehdashti, Farrokh

doi:10.2967/jnumed.115.157933

Cited by 44 publications

(33 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tracer uptake did not correlate with PR expression levels in the tumors and the overall target/background ratio was very low which together resulted in clinical application failure [ 66 , 67 ]. [ 18 F]FFNP is more promising as it has a higher binding affinity to PR and less unspecific binding [ 68 ]. An ongoing Phase II study is evaluating [ 18 F]FFNP-PET/MRI for imaging of PR expression in invasive BCa patients (NCT03212170).…”

Section: Direct Targeting Of Tumor Cellsmentioning

confidence: 99%

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Heesch

Maurer

Stickeler

et al. 2020

Cells

View full text Add to dashboard Cite

Molecular imaging plays an increasingly important role in the diagnosis and treatment of different malignancies. Radiolabeled probes enable the visualization of the primary tumor as well as the metastases and have been also employed in targeted therapy and theranostic approaches. With breast cancer being the most common malignancy in women worldwide it is of special interest to develop novel targeted treatments. However, tumor microenvironment and escape mechanisms often limit their therapeutic potential. Addressing tumor stroma associated targets provides a promising option to inhibit tumor growth and angiogenesis and to disrupt tumor tissue architecture. This review describes recent developments on radiolabeled probes used in diagnosis and treatment of breast cancer especially in triple negative type with the focus on potential targets offered by the tumor microenvironment, like tumor associated macrophages, cancer associated fibroblasts, and endothelial cells.

show abstract

Section: Direct Targeting Of Tumor Cellsmentioning

confidence: 99%

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Heesch

Maurer

Stickeler

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…For example, the dihydrotestosterone analog 18 F-fluoro-5-dihydrotestosterone ( 18 F-FDHT) binds with high selectivity to AR, and importantly, 18 F-FDHT PET imaging was able to quantify the pharmacodynamics of new antiandrogens in clinical studies (72). The same is true of other hormone receptors, including the estrogen receptor and the progesterone receptor, for which PET tracers have been developed and have shown utility in measuring early responses to hormone therapy (73).…”

Section: Imaging Androgen Receptor Signalingmentioning

confidence: 72%

Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine

et al. 2017

View full text Add to dashboard Cite

Comprehensive molecular analysis of individual tumors provides great potential for personalized cancer therapy. However, the presence of a particular genetic alteration is often insufficient to predict therapeutic efficacy. Drugs with distinct mechanisms of action can affect the biology of tumors in specific and unique ways. Therefore, assays that can measure drug-induced perturbations of defined functional tumor properties can be highly complementary to genomic analysis. PET provides the capacity to noninvasively measure the dynamics of various tumor biologic processes in vivo. Here, we review the underlying biochemical and biologic basis for a variety of PET tracers and how they may be used to better optimize cancer therapy.

show abstract

“…Prognostic factors help to distinguish which tumors are most likely to progress to tumor spread and death. Some examples of prognostic factors in breast cancer are ER, PR, and HER2 receptor status, proliferation index, and Oncotype DX 21-gene panel (6)(7)(8).…”

Section: Prognostic Factors and Breast Cancermentioning

confidence: 99%

“…L-methyl-11 C-methionine ( 11 C-MET) is an amino acid used in PET, and a small number of cases were found to have decreased 11 C-MET uptake after treatment with endocrine therapy or chemotherapy (71)(72)(73). Numerous others have a potential important role in the development and optimization of targeted therapies (7,54).…”

Section: Assessment Of Early Response (Pharmacodynamics)mentioning

confidence: 99%

Molecular Imaging and Precision Medicine in Breast Cancer

Chudgar

Mankoff

2017

PET Clinics

View full text Add to dashboard Cite

distributed among women with breast cancer [28-30]. Molecular subtypes are not only associated with different tumor phenotypes but also with distinct variations in response to therapy and patient survival. Accordingly, subtype-based recommendations for sys-temic therapies have now been implemented in clinical practice [28-31]. To match advanced therapeutic strategies in the era of precision medicine, diagnostic tests must be equally multilayered and complex to identify the underlying functional processes of cancer development and progression. However, with conventional imaging methods such as mam-mography, DBT, and sonography, which are qualitative tests that detect morphologic, non-specific tissue changes, the assessment and comprehension of breast cancer in all its diversity is not possible. To overcome these limitations, functional imaging techniques to improve breast cancer diagnosis have been explored. In this context , magnetic resonance imaging (MRI) has emerged as an exceptionally powerful, versatile, and precise imaging technique. MRI is an essential non-invasive technique in breast imaging with multiple established indications, such as pre-operative staging of breast cancer, evaluation of therapy response in patients receiving neoad-juvant treatment, differentiation between scar tissue and tumor recurrence , examination of patients with breast implants, and screening of high-risk patients [1, 5]. Dynamic contrast-enhanced MRI of the breast provides both high-resolution morphologic and functional quantitative information on neovascularity as a tumor-specific feature [32-35]. MRI is the most sensitive exam for the detection of breast cancer in women at any given risk [32-36] and often detects cancers that are occult in mammography, DBT and sonog-raphy [37, 38]. Due to these excellent results specific screening programs for high-risk women that include both annual mammogra-phy and MRI have been developed [32, 39] and there is discussion about screening of women at average of risk cancer with abbreviated MRI protocols [40-42]. In addition to breast cancer detection there is evidence that quantitative dynamic contrast enhanced (DCE)-MRI models are useful in the assessment and prediction of Breast cancer is the most common cancer in women, the 2nd leading cause of female cancer deaths and thus remains a major medical and socioeconomic burden. Medical imaging has always been an integral part in breast cancer care ranging from diagnosis and staging to therapy monitoring and post-therapeutic follow-up [1-5]. Screening mammography has significantly contributed to the detection of breast cancer especially at an early, prognostically favorable stage and mammography has been demonstrated to reduce breast cancer mortality [6-9]. Mammography is relatively inexpensive and widely available. However, its sensitivity is limited, ranging from 70 to 85% [10-12] overall but is significantly reduced to 30-50% in women with dense breasts, which can be attributed to the 'masking effect' of dense breast tissue. This effect is d...

show abstract

Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer

Cited by 44 publications

References 40 publications

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target

Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine

Molecular Imaging and Precision Medicine in Breast Cancer

Contact Info

Product

Resources

About